Substantial uncertainty had existed about the long-term benefits of cholesterol-lowering drug therapy for particular types of patient, and the extent of its use is limited. Uncertainty as to the possible benefits, or risks, of antioxidant vitamin supplementation was even greater.
To help resolve these uncertainties, the MRC/BHF Heart Protection Study was designed to be really large, to involve a substantial reduction in blood LDL cholesterol levels and a substantial increase in antioxidant vitamin levels, and to include a wide range of patients at substantial risk of death from heart disease and other causes. It provides reliable evidence about the effects of these cholesterol-lowering treatments and antioxidant vitamin supplements on mortality and major morbidity in a wide range of circumstances.
MRC/BHF Heart Protection Study Collaboration, Writing committee, Hopewell JC, Parish S, Clarke R, Armitage J, et al. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J Am Coll Cardiol. 2011; 57(20): 2000-7.
Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, et al. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet. 2011; 4(1): 68-73.
Heart Protection Study Collaborative Group, Writing committee, Bulbulia R, Bowman L, Wallendszus K, Parish S, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011; 378(9808): 2013-20.
Parish S, Offer A, Thompson A, Link E, Di Angelantonio E, Bowman L, et al. Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med. 2010; 268(4): 348-58.